Quick Answer
Zenas BioPharma, Inc. reported Total Revenue of $10.00 million for fiscal year 2025.
Zenas BioPharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $10.00M +100.0% |
$5.00M -90.0% |
$50.00M | — |
| Revenue (ASC 606) | $10.00M +100.0% |
$5.00M -90.0% |
$50.00M | — |
| Net Income | -$377.74M -140.6% |
-$156.99M -322.9% |
-$37.12M | — |
| Diluted EPS | -$8.44 +29.0% |
-$11.89 +51.0% |
-$24.25 | — |
| Total Assets | $383.64M +3.7% |
$369.97M +442.6% |
$68.18M | — |
| Cash and Equivalents | $110.64M -65.4% |
$319.74M +462.4% |
$56.86M | — |
| Long-Term Debt | $78.64M | — | — | — |
| Stockholders Equity | $242.14M -22.5% |
$312.46M +238.4% |
-$225.72M -17.4% |
-$192.29M |
| R&D Expense | $168.06M +20.8% |
$139.14M +131.8% |
$60.03M | — |
| Operating Income | -$383.06M -133.7% |
-$163.89M -341.2% |
-$37.15M | — |
| Shares Outstanding | 54.49M +30.4% |
41.79M +2550.4% |
1.58M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | March 31, 2025 | $10.00M | — | -80.0% |
| Net Income | September 30, 2025 | -$51.50M | -33.4% | +1.4% |
| Diluted EPS | September 30, 2025 | -$1.22 | +75.7% | +2.4% |
| Total Assets | September 30, 2025 | $322.02M | -20.2% | +9.9% |
| Cash and Equivalents | September 30, 2025 | $115.56M | -67.9% | +162.6% |
| Long-Term Debt | September 30, 2025 | $72.99M | — | — |
| Stockholders Equity | September 30, 2025 | $196.43M | -45.4% | -18.0% |
| R&D Expense | September 30, 2025 | $34.40M | +2.6% | -20.0% |
| Operating Income | September 30, 2025 | -$52.58M | -28.3% | +4.7% |
| Shares Outstanding | September 30, 2025 | 42.21M | +1.0% | +0.3% |
- Zenas BioPharma, Inc. reported Total Revenue of $10.00 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed an increase of +100.0% in Total Revenue compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Revenue (ASC 606) of $10.00 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed an increase of +100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Net Income of -$377.74 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed a decrease of -140.6% in Net Income compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Diluted EPS of $8.44 per share (loss) for fiscal year 2025.
- Zenas BioPharma, Inc. showed an increase of +29.0% in Diluted EPS compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Total Assets of $383.64 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed an increase of +3.7% in Total Assets compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Cash and Equivalents of $110.64 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed a decrease of -65.4% in Cash and Equivalents compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Long-Term Debt of $78.64 million for fiscal year 2025.
- Zenas BioPharma, Inc. reported Stockholders Equity of $242.14 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed a decrease of -22.5% in Stockholders Equity compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported R&D Expense of $168.06 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed an increase of +20.8% in R&D Expense compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Operating Income of -$383.06 million for fiscal year 2025.
- Zenas BioPharma, Inc. showed a decrease of -133.7% in Operating Income compared to the prior fiscal year.
- Zenas BioPharma, Inc. reported Shares Outstanding of 54.49 million shares for fiscal year 2025.
- Zenas BioPharma, Inc. showed an increase of +30.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: